Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Relay Therapeutics Inc (NASDAQ: RLAY) saw premarket gains after Oppenheimer upgraded the stock from Perform to Outperform and set a $14.00 price target. Analyst Matt Biegler pointed to a possible competitive tailwind for Relay's mutant-selective PI3K inhibitor zovegalisib if gedatolisib's upcoming VIKTORIA-1 readout disappoints in PI3K-mutant patie…
Stilwell Joseph, identified as a 10% owner of Peoples Financial Corp (NASDAQ: PFBX), acquired 1,840 shares of the company's common stock on January 23, 2026, at $20.50 per share, for a total cash outlay of $37,720. The filing details Stilwell's aggregate holdings through multiple Stilwell-managed investment vehicles and includes a disclaimer regard…
JPMorgan raised its price target on Apple to $315 from $305 and retained an Overweight rating, citing expectations for stronger iPhone revenues and increased earnings power. The firm projects 16% growth in iPhone revenue and anticipates only modest margin impact from higher memory costs, noting supplier contracts and scale advantages. Apple reports…
JPMorgan reduced its price target for Varonis Systems to $50 from $62 while retaining an Overweight rating and placing the stock on Positive Catalyst Watch ahead of the company’s fourth-quarter earnings. The bank expects new SaaS-specific disclosures to clarify the trajectory of recurring revenue after the company’s third-quarter weaknesses in on-p…
JPMorgan increased its price target on SLB to $54 from $43 while maintaining an Overweight rating, backing the oilfield services company's 2026 guidance. Management expects improvements in three international problem areas that weighed on 2025 results - Saudi Arabia, Mexico and deepwater operations - and sees growth driven by its Digital segment, P…
JPMorgan has kept Overweight ratings on Digital Realty Trust and Equinix, maintaining December 2026 price targets at $210 and $950 respectively while modestly raising 2026 revenue and profitability estimates. The bank points to pricing strength in a capacity-constrained environment and new lease signings as drivers for improved stock performance in…
Cipher Mining (CIFR) has rallied hard off its 2025 lows, and the market is no longer treating it like a pure-play bitcoin miner. With a growing development pipeline and headlines around AI/HPC hosting, the setup for 2026 is straightforward: execution has to replace speculation. This trade idea leans long, using nearby technical levels and high liqu…
President Donald Trump announced he is sending border czar Tom Homan to Minnesota following a weekend incident in Minneapolis in which immigration agents fatally shot a U.S. citizen. The president said Homan will travel Monday night, described him as "tough but fair," and indicated Homan will report directly to him. Trump also referenced ongoing pr…
Shares of German space technology company OHB SE rose 27% to their highest-ever level after the firm confirmed it is engaged in discussions with Rheinmetall Group. The talks center on potential cooperation tied to participation in public procurement processes. OHB provided no further specifics on the scope or timing of the possible partnership, lea…
DA Davidson moved BOK Financial (BOKF) from a Buy to a Neutral rating even as it increased its one-year price target to $135 from $125. The broker pointed to constrained upside after reworking its valuation to a forward multiple tied to 2027 earnings, despite projecting among the highest 2026-2027 EPS forecasts and flagging several positive operati…
James T. Gottwald, identified as a ten percent owner of Tredegar Corporation (TG), disposed of 79,092 shares across two days in late January 2026 for roughly $683,494. The Form 4 filing details the tranches, weighted average prices and price ranges. Following the sales, Gottwald retains a mix of direct and indirect holdings across several trusts an…
Merck & Company halted negotiations to buy Revolution Medicines after both sides could not agree on price. The breakdown in talks, reportedly tied to valuation differences, sent Revolution Medicines shares sharply lower in premarket trading. The biotech continues clinical work on RAS-targeting drugs, with key data due in the first half of the year,…
John D. Gottwald, a roughly 10% owner of Tredegar Corporation, sold 79,092 shares of common stock on January 22 and 23, 2026, for a total of $683,494, according to a Form 4 filing. The transactions leave Gottwald with substantial direct and indirect holdings, while the company navigates a scheduled CEO transition and trades near InvestingPro's fair…
Research from Lynx Equity Strategy cautions that Apple may encounter further pressure on profitability after supply tensions over NAND flash memory caused by deteriorating talks with supplier Kioxia. The firm says those frictions could prompt higher costs from alternative vendors, notably Samsung, and raise technical compatibility risks that may af…
Redburn Atlantic upgraded Meta Platforms to Buy and lifted its target to $900 from $740, arguing that market anxiety about rising artificial intelligence spending has obscured the company's longer-term earnings potential. The firm raised its FY26 cost and capex estimates, cautioned on near-term EPS headwinds, but highlighted durable advertising str…
Expedia (EXPE) has sold off from its early-January peak even after strong results and raised guidance. With improving U.S. demand commentary in recent coverage, expanding profitability, and a valuation that looks more reasonable on cash flow than the headline P/E implies, the risk-reward favors a defined long setup. The trade plan below focuses on …
Clear Street increased its price objective on Krystal Biotech (KRYS) to $338 from $288 and kept a Buy rating, pointing to investor enthusiasm for the company's pipeline, notably KB801 for Neurotrophic Keratitis. The firm now forecasts $2.0 billion in peak sales for KB801 by 2040 and raised the therapy's likelihood of success to 50%. Krystal's recen…
UBS reiterated a Buy rating on Chipotle Mexican Grill with a $45.00 price target, warning of margin pressure in the fourth quarter and into 2026. The bank's forecasts project narrower restaurant margins driven by subdued sales, rising beef costs and stepped-up marketing investment, partially offset by operational efficiencies. Other firms including…
Guggenheim increased its price target on Starbucks to $90 from $88 and kept a Buy rating as the coffee chain prepares for fiscal Q1 2026 results and an Investor Day. The stock is trading above the new target, recent analyst actions are mixed, and the company announced a quarterly dividend ahead of the scheduled disclosures.
TD Cowen reduced its target for SkyWest (NASDAQ: SKYW) to $122 from $132 while retaining a Buy rating. The revised target implies roughly 20% upside from the current share price of $101.66. The change precedes SkyWest's fourth quarter 2025 earnings release on January 29 and reflects adjustments to 2026 forecasts after a December update to Q4 2025 e…
Abbott Laboratories Chairman and CEO Robert B. Ford reported a personal purchase of 18,800 shares on January 23, 2026, totaling $2,013,966. The transaction occurred in a price band of $106.735 to $107.485 and leaves Ford with 253,305 shares directly and 216,203 indirectly through the Ford Family Trust. The trade coincides with multiple analyst upda…
ConocoPhillips is back near $100 with a constructive technical base and valuation metrics that still look more “cash machine” than “bubble.” With a 3%+ dividend yield, moderate leverage, and a trend that has been grinding higher above key moving averages, COP sets up as a mid-term long where the reward can be defined against a clean stop.
Jefferies raised its price objective for Bloom Energy to $92 from $53 while retaining an Underperform rating. The revision rests on higher 2026 revenue estimates driven by orders from American Electric Power and Quanta, but the firm warns that lofty market expectations, extreme volatility and limited valuation headroom mean investors will be watchi…
Oatly has been left for dead after a long slide from its 52-week high, and the chart still reads heavy. But the stock is starting to look like a classic “comeback nobody is pricing in” setup: RSI is cooling near the low-40s, momentum is still bearish but stabilizing, and short interest has been trending down meaningfully into year-end. With OTLY si…
Abbott Laboratories Chairman and CEO Robert B. Ford acquired 18,800 common shares on January 23, 2026, for approximately $2.01 million. The move comes as the company reported weaker-than-expected fourth-quarter results and multiple analysts adjusted price targets and outlooks amid revenue and earnings shortfalls.
